NKTR Earning Date, Earning Analysis and Earning Prediction
Earning Analysis
Welcome to our in-depth analysis of Nektar Therapeutics(NKTR) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Nektar Therapeutics earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
Name
EPS
Revenue
Price Reaction
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2025Q3
2025-11-06
After Hours
-2.85
-1.85
+35.09
10.20M
11.79M
+15.62
+1.54
+4.63
FY2025Q2
2025-08-07
After Hours
-3.13
-2.95
+5.75
9.42M
11.18M
+18.68
+6.02
+18.25
FY2025Q1
2025-05-08
After Hours
-0.18
-0.24
-33.33
15.36M
10.46M
-31.88
-4.88
+15.53
FY2024Q4
2025-03-12
After Hours
-0.13
-0.15
-15.38
36.66M
29.18M
-20.41
-0.56
+9.41
FY2024Q1
2024-05-09
-
-0.21
-0.18
+14.29
15.34M
21.64M
+41.05
-2.44
+11.59
FY2023Q4
2024-03-04
-
-0.20
-0.22
-10.00
21.37M
23.89M
+11.78
+15.38
+16.67
FY2023Q3
2023-11-07
-
-0.18
-0.19
-5.56
21.31M
24.14M
+13.28
+3.77
-15.09
FY2023Q2
2023-08-08
-
-0.30
-0.27
+10.00
21.83M
20.50M
-6.08
-1.96
-19.61
-
2023-05-09
-
-0.26
-0.25
+3.85
-
-
-
-
-1.30
-
2023-02-28
-
-0.45
-0.32
+28.89
-
-
-
-0.72
+3.60
NKTR Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Nektar Therapeutics reported performance for FY2025Q3, announced on 2025-11-06. The company achieved an EPS of -1.85, compared to analyst estimates of -2.85 by 35.09% . Revenue for the quarter reached 11.79M compared to expectations of 10.20M by 15.62% .
The stock price reacted with a 1.54% one-day change and a 4.63% five-day change following the earnings release. These movements reflect market reaction in Nektar Therapeutics growth trajectory and strategic initiatives.
NKTR Earnings Forecast
Looking ahead, Nektar Therapeutics(NKTR) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 10.44M and an EPS of -2.36.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 3.72%, while EPS estimates have been Revise Downward by -15.36%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -9.44% . These revisions correlate with a -2.31% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Nektar Therapeutics long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between NKTR's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+3.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-15.36%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-9.44%
In Past 3 Month
Stock Price
Go Down
-2.31%
In Past 3 Month
1Y
3Y
5Y
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:43.85M
--
EPS Estimate-Annual FY 2025:-10.05
—
Stock Price48.74
NKTR Revenue and EPS Performance: A Historical Perspective
Nektar Therapeutics revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-06,After Hours):
EPS: -1.85 (Actual) vs.-2.85 (Estimate) (35.09%)
Revenue: 11.79M (Actual) vs. 10.20M (Estimate) (15.62%)
Price Reaction:1.54%(1-Day), 4.63%(5-Day)
FY2025Q2 (2025-08-07,After Hours):
EPS: -2.95 (Actual) vs.-3.13 (Estimate) (5.75%)
Revenue: 11.18M (Actual) vs. 9.42M (Estimate) (18.68%)
Price Reaction:6.02%(1-Day), 18.25%(5-Day)
FY2025Q1 (2025-05-08,After Hours):
EPS: -0.24 (Actual) vs.-0.18 (Estimate) (-33.33%)
Revenue: 10.46M (Actual) vs. 15.36M (Estimate) (-31.88%)
Price Reaction:-4.88%(1-Day), 15.53%(5-Day)
Earnings Reaction
The chart below shows how NKTR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NKTR sees a +6.83% change in stock price 10 days leading up to the earnings, and a -4.03% change 10 days following the report. On the earnings day itself, the stock moves by +1.43%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 1.54% on the day following the earnings release and then changed by -0.02% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
People Also Watch
Frequently Asked Questions
What were the key highlights of NKTR's latest earnings report for FY2025Q3?
NKTR reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 11.79M against an estimate of 10.20M, resulting in a 15.62% surprise. The EPS was -1.85, surpassing the expected -2.85 by 35.09% . The stock experienced a 1.54% price change on the earnings day and a 4.63% change over the next five days, reflecting market reactions to the results.
How did NKTR's stock price react after the FY2025Q3 earnings release?
Following NKTR's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 1.54% on the day of the release. Over the subsequent five days, it saw a 4.63% change. Historically, NKTR's stock price tends to shift by an average of +6.83% in the 10 days leading up to earnings and -4.03% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for NKTR for 2025/Q4?
For 2025/Q4, analysts estimate NKTR’s annual revenue to reach 10.44M, while the EPS is projected at -2.36. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.72% and EPS estimates Revise Downward by -9.44% over the past three months, indicating analyst expectation in the company’s performance.
How does NKTR's stock price correlate with earnings forecast revisions?
The correlation between NKTR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 3.72%, while EPS estimates moved Revise Downward by -9.44% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from NKTR's next earnings report?
Based on historical trends, NKTR's stock price typically moves by +6.83% in the 10 days before its earnings and -4.03% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -2.36 and revenue of 10.44M.
What is the sentiment in Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Summary?
Despite some unclear management responses, the earnings call highlights strong market opportunities for REZPEG, particularly in atopic dermatitis and alopecia areata. The company's financial guidance shows a healthy cash runway, and the potential differentiation of REZPEG from competitors is promising. The Q&A section reveals significant interest in REZPEG's unique mechanism and its potential safety advantages over JAK inhibitors. Overall, these factors suggest a positive sentiment towards Nektar's future prospects, supporting a positive stock price movement prediction.
